Argenx 1H22: Veni, vidi, Vyvgart!
In its 1H22 figures, argenx makes a slam dunk with the commercial uptake of their FcRn inhibitor Vyvgart for the treatment of generalized myasthenia gravis (gMG). The company also takes its next steps into immune thrombocytopenia (ITP) as competitor UCB steps out of the race and sets cusatuzumab free in a new spin-off. As a result, we increase our commercial expectations for the coming years and raise our target price to €400, Buy rating re-iterated.Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.